Core Viewpoint - Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. plans to reduce its stake in Shanhe Pharmaceutical Auxiliary Co., Ltd. by up to 6,978,729 shares, representing no more than 3% of the company's total share capital, excluding repurchased shares [1] Summary by Relevant Sections - **Share Reduction Plan** - The reduction will occur through centralized bidding and block trading methods within a period of 90 days starting from November 24, 2025, to February 21, 2026 [1] - **Share Capital Details** - The total shares to be reduced are calculated based on the company's total share capital, excluding 1,825,500 shares that have been repurchased [1]

Core Viewpoint - Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., a shareholder holding 9.23% of Shanhe Pharmaceutical Auxiliary (300452.SZ), plans to reduce its stake by up to 6.9787 million shares, representing 3.00% of the company's total share capital, due to its own funding needs [1] Summary by Sections Shareholder Reduction Plan - The reduction will occur through centralized bidding and block trading methods within 90 days starting from 15 trading days after the announcement, specifically from November 24, 2025, to February 21, 2026 [1] - In any consecutive 90-day period, the block trading reduction will not exceed 2% of the company's total share capital (4.6525 million shares), while the centralized bidding reduction will not exceed 1% (2.3262 million shares) [1]

证券代码：300452 证券简称：山河药辅 公告编号：2025-059 债券代码：123199 债券简称：山河转债 安徽山河药用辅料股份有限公司 （二）股东持股情况：截至本公告日，复星医药持有公司股份 21,645,259 股，占公司总股本的比例为 9.23%。 二、本次减持计划的主要内容 1、拟减持原因：自身资金需求。 关于 5%以上股东减持股份计划的预披露公告 公司 5%以上股东上海复星医药产业发展有限公司保证向本公司提 供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的 信息一致。 特别提示： 持安徽山河药用辅料股份有限公司（以下简称"公司"或"本公 司"）股份 21,645,259 股（占公司总股本比例 9.23%）的股东上海 复星医药产业发展有限公司（以下简称"复星医药"），拟自公告发 布之日起 15 个交易日后 90 日内（2025 年 11 月 24 日至 2026 年 2 月 21 日）以集中竞价交易方式和大宗交易方式合计减持本公司股份 不超过 6,978,729 股，即不超过公司总股本（扣除公司回购股份 1,825, ...

证券代码:300452 证券简称:山河药辅 公告编号：2025-058 债券代码:123199 债券简称:山河转债 安徽山河药用辅料股份有限公司 关于公司原控股股东、实际控制人股份继承过户完成的公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏。 特别提示： 1、本次股份非交易过户系因安徽山河药用辅料股份有限公司（以 下简称"公司"）原控股股东、实际控制人、董事长尹正龙先生逝世 后的遗产继承所致，其继承人通过继承的方式获得上市公司股份，不 会对公司产生重大不利影响。截至本公告披露日，尹正龙先生生前所 持公司股份继承过户已完成。 2、公司原控股股东、实际控制人、董事长尹正龙先生于 2025 年 8 月 26 日逝世，尹正龙生生前持有的公司 63,057,454 股股份，由 其妻子吴长虹女士继承 47,293,091 股股份，占公司总股本的 20.172%，其女儿尹稚雅女士继承 15,764,363 股股份，占公司总股 本的 6.724%。吴长虹女士与尹稚雅女士签署了《表决权委托协议》， 尹稚雅女士将其所持有山河药辅全部股份的身份性权利，包括（但不 限于）参会权、提名权、提案权 ...

近日，山河药辅发布三季报。2025年第三季度公司实现营业收入2.26亿元，同比增长16.06%；归属于上 市公司股东的净利润为3952.88万元，同比增长46.99% 前三季度营收为6.97亿元，同比增长8.09%；净利润为1.33亿元，同比增长8.28%。 （山河药辅公告） (编辑：杨燕 林辰)关键字： 医药 ...

Core Viewpoint - The company, Shanhe Pharmaceutical (300452), announced the nomination of Ms. Wu Changhong as a candidate for the sixth board of directors as a non-independent director [1] Summary by Relevant Sections - **Company Announcement** - The board of directors of Shanhe Pharmaceutical has approved the nomination of Ms. Wu Changhong for the position of non-independent director [1]

Core Points - The company reported a revenue of 697 million yuan for the first three quarters of 2025, representing a year-on-year growth of 8.09% [1] - The net profit attributable to shareholders for the same period was 133 million yuan, with a year-on-year increase of 8.28% [1] - In the third quarter alone, the company achieved a revenue of 226 million yuan, marking a year-on-year growth of 16.06% [1] - The net profit for the third quarter was approximately 39.53 million yuan, showing a significant year-on-year increase of 46.99% [1]

Core Insights - The company reported a revenue of 225,663,160.30 yuan for the third quarter of 2025, representing a year-on-year growth of 16.06% [2] - The net profit attributable to shareholders of the listed company was 39,528,758.33 yuan, showing a significant year-on-year increase of 46.99% [2] Financial Performance - Revenue for Q3 2025: 225.66 million yuan, up 16.06% year-on-year [2] - Net profit for Q3 2025: 39.53 million yuan, up 46.99% year-on-year [2]

Group 1 - Yonghe Co., Ltd. reported a net profit of 469 million yuan for the first three quarters, a year-on-year increase of 220.39% [1] - Jinli Permanent Magnet achieved a net profit of 515 million yuan, reflecting a year-on-year growth of 161.81% [1][2] - Sanhe Pharmaceutical Auxiliary's net profit increased by 8.28% year-on-year, reaching 133 million yuan [2] Group 2 - Jiahuan Technology experienced a net profit decline of 26.53%, totaling 55.35 million yuan [3] - Wuchan Huaneng reported a net profit decrease of 15.10%, amounting to 453 million yuan [3] - Chuan Investment Energy's net profit fell by 4.54%, totaling 4.22 billion yuan [4][5] Group 3 - Dayang Bio's net profit grew by 56.12%, reaching 80 million yuan [5] - Weili Medical reported a net profit increase of 14.94%, totaling 192 million yuan [6] - People's Tongtai's net profit decreased by 45.69%, amounting to 112 million yuan [7] Group 4 - Jiuhuan Bio received a medical device registration certificate for its NT-proBNP test kit [8] - Jincheng Pharmaceutical's subsidiary obtained a drug registration certificate for a specific injection [9] - Guangdian Yuntong's subsidiary acquired a money service operator license in Hong Kong [10] Group 5 - Dash Intelligent won a bid for a project worth 96 million yuan related to the Shijiazhuang subway [10] - Alloy Investment's net profit increased by 124.87%, reaching 7.26 million yuan [11] - Kaile Co., Ltd. reported a net profit growth of 159.14%, totaling 21.63 million yuan [12] Group 6 - Chuanjinno's net profit surged by 175.61%, reaching 304 million yuan [14] - Rijiu Optoelectronics reported a net profit increase of 36.54%, totaling 76.91 million yuan [15] - Dazhu CNC's net profit grew by 142.19%, amounting to 492 million yuan [15] Group 7 - Nairui Radar expects a net profit increase of 181% for the first three quarters [17] - Suzhou Tianmai successfully acquired land use rights for a new manufacturing project [19] - Aokai Pharmaceutical announced clinical research data for its innovative drug at a major conference [21][22] Group 8 - Jilin Aodong's subsidiary passed the consistency evaluation for a specific injection [24] - Qinxin Environment announced the resignation of a board member [25] - *ST Baoying is planning a change in control, leading to a stock suspension [26] Group 9 - Jianlang Hardware's director plans to reduce holdings by up to 500,000 shares [27] - Taihe Technology's director intends to reduce holdings by up to 606,000 shares [29] - Zhongyuan Securities announced a cash dividend of 0.008 yuan per share [31] Group 10 - Beijing-Shanghai High-Speed Railway plans to distribute a cash dividend of 0.0385 yuan per share [32] - Zhuhai Guanyu expects a net profit increase of 36.88%-55.54% for the first three quarters [34] - Shenglong Co., Ltd. reported a net loss of 72.95 million yuan for the first three quarters [36] Group 11 - Shuangyuan Technology plans to distribute a cash dividend of 0.125 yuan per share [38] - Shaanxi Guotou A reported a net profit increase of 6.6%, totaling 996 million yuan [40] - Sunshine Nuohua intends to invest 15 million yuan in a biotech company [41] Group 12 - Yangjie Technology's net profit increased by 45.51%, reaching 974 million yuan [42] - Xingwang Yuda reported a net profit growth of 260%, totaling 38.37 million yuan [43] - Tongyou Technology turned a profit with a net profit of 9.29 million yuan [44]

人民财讯10月20日电，山河药辅（300452）10月20日发布2025年第三季度报告，公司第三季度实现营业 收入2.26亿元，同比增长16.06%；归母净利润3952.88万元，同比增长46.99%。前三季度实现营业收入 6.97亿元，同比增长8.09%；归母净利润1.33亿元，同比增长8.28%。 ...